Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 16, 2008 Brian Lawler	Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note.
Pharmaceutical Executive March 1, 2006 Ron Feemster	Holding Their Breath: Inhaled Insulin Exubera, Pfizer's inhaled-insulin therapy, is carving out a new market for diabetes drugs. Four more companies are looking for their share.
The Motley Fool June 19, 2009 Robert Steyer	MannKind Needs More Leaps Getting FDA approval for its inhaled-insulin product is only one hurdle for this start-up pharmaceutical.
The Motley Fool January 13, 2006 Stephen D. Simpson	Pfizer Pays Sanofi to Go Away Two large pharmaceutical companies settle a dispute over inhaled insulin, and $1.3 billion changes hands. Investors, take note.
The Motley Fool September 19, 2006 Brian Lawler	A Long Wait for MannKind The company's inhaled insulin might not reach the market for several years, if it does, but it's a big market. Investors, take note.
Pharmaceutical Executive May 1, 2009	The Fate of Mannkind Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded?
The Motley Fool September 9, 2005 Stephen D. Simpson	Diabetics Breathing Easier Investors in Pfizer, Sanofi-Aventis, and Nektar Therapeutics might be breathing a bit easier today. The FDA's expert panel recommended approval for Exubera.
The Motley Fool September 22, 2010 Brian Orelli	Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown.
The Motley Fool July 30, 2010 Brian Orelli	MannKind: Strengths, Weaknesses, Opportunities, Threats It's all about the inhaled insulin.
The Motley Fool April 14, 2008 Brian Lawler	MannKind Gets Smacked by Big Brother's Bad News Bad news for a competitor sinks MannKind shares.
The Motley Fool July 27, 2007 Rich Duprey	Sniffing Out Bentley's New Patent To succeed in insulin therapy, the generic drugmaker must overcome patent expiration. Investors, take note.
The Motley Fool December 5, 2008 Brian Orelli	Be Kind to MannKind MannKind has good data on its inhaled insulin drug, but will the FDA approve of it and will diabetics buy it?
The Motley Fool December 27, 2011 Brian Orelli	2011 No Dreamboat for MannKind An FDA rejection and a long wait is a bad combination.
The Motley Fool May 22, 2006 Stephen D. Simpson	Nektar Full of Potential, Risk Can inhaled insulin sales live up to investors' expectations at Nektar Therapeutics?
The Motley Fool June 27, 2011 Brian Orelli	Data Galore, but Where's the FDA Approval? Presentations at the American Diabetes Association won't help with approvals.
The Motley Fool May 6, 2008 Brian Lawler	MannKind Moves Ahead The pharmaceutical awaits pivotal data on its lead drug Technosphere.
The Motley Fool November 13, 2007 Brian Lawler	Nektar's New Old Drug Pfizer returns its non-selling inhalable insulin experiment Exubera to Nektar Therapeutics today, along with $135 million in cash.
The Motley Fool March 16, 2010 Brian Orelli	How to Lose $114 Million in One Day You've got to be a very trusting investor to buy shares in pharmaceutical company, MannKind.
The Motley Fool March 6, 2008 Brian Lawler	2008 Should Make or Break MannKind MannKind updates investors on what to expect this year.
Chemistry World June 30, 2014 Phillip Broadwith	Inhaled insulin approved in US Mannkind's Affreza is aimed at reducing the need for patients to inject themselves with insulin so frequently.
The Motley Fool April 10, 2008 Brian Lawler	Nektar Can't Squeeze Nectar From This Drug Nektar Therapeutics announced that it was putting its inhaled insulin drug, Exubera, to rest. Investors, take note.
The Motley Fool June 11, 2010 Brian Orelli	Double-Digit Pop Because the Drug Still Works? Developments at Mannkind's shareholder meeting send stock soaring.
The Motley Fool June 29, 2011 Brian Orelli	So Much Insulin, So Little Use for It MannKind settles its supply agreement with Merck.
The Motley Fool March 2, 2005 Bill Mann	How Hated Is Pfizer? The FDA accepts Pfizer's application for what could be a monster drug, and the market yawns.
The Motley Fool August 12, 2005 Stephen D. Simpson	Novo Nordisk Perks Up This leading insulin company rebounds from a sluggish first quarter. For investors willing to buy and hold a stock for years, Novo Nordisk could still be an interesting play on a serious and growing disease market.
The Motley Fool May 10, 2011 Brian Orelli	Waiting for MannKind's Pot of Gold It's going to be awhile.
The Motley Fool April 28, 2005 Stephen D. Simpson	Novo Nordisk Could Use a Boost Investors reacted badly to first-quarter results, but there's still a lot to like about the Danish pharmaceutical.
The Motley Fool July 19, 2007 Brian Orelli	Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts.
The Motley Fool October 27, 2005 Stephen D. Simpson	What's New With Novo? Novo Nordisk is a good play on diabetes, but will new drugs reduce the need for insulin? Investors, take note.
The Motley Fool January 27, 2006 Stephen D. Simpson	Challenges Needle Novo Nordisk The insulin franchise is attractive, but under threat. Guidance for 2006 wasn't impressive and there are definite challenges ahead. Investors, take note.
The Motley Fool June 29, 2009 Brian Orelli	Lantus Results: Reply Hazy, Try Again Later Drugmaker Sanofi's problems become murkier. Investors are relieved that the data is out -- Sanofi is up about 4.5% at the moment -- but it seems prudent to be cautious here.
The Motley Fool December 31, 2009 Brian Orelli	2010 FDA Decisions to Watch It's a pivotal year for these drugmakers.
BusinessWeek July 17, 2006 Arlene Weintraub	From Pfizer, Irrational Exubera? Pfizer's insulin inhaler may not be as big a diabetes blockbuster as expected.
The Motley Fool June 27, 2008 Brian Lawler	This Drug Market Is Booming One therapeutic category seems to be expanding significantly faster than most of its peers, the one that helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide.
The Motley Fool August 6, 2007 Brian Lawler	Unhappy Delays for MannKind Two delays for the inhalable insulin developer cause the stock to drop.
The Motley Fool October 19, 2007 Brian Lawler	The Exubera Winner In its third-quarter earnings report, Pfizer announces it is surrendering the rights to market inhalable-insulin treatment Exubera to developer Nektar Therapeutics. Investors, take note.
The Motley Fool March 20, 2008 Brian Lawler	The AIR's Knocked Out of Alkermes Drug developer Alkermes initiates a round of cost-cutting.
The Motley Fool September 6, 2005 Stephen D. Simpson	FDA's Eye on 2 Potential Blockbusters This week, FDA advisory panels will consider the marketing approval applications of Exubera, the inhaled insulin from Pfizer/Sanofi/Nektar, and Pargluva, the dual PPAR agonist, taken in pill form, from Bristol-Myers and Merck. Investors, take note.
The Motley Fool June 11, 2007 Brian Lawler	More Air for Alkermes The biopharmaceutical drug delivery expert brings another drug into clinic stage testing. Investors, take note.
The Motley Fool October 31, 2008 Brian Orelli	Disease Is Good for Novo Nordisk The Danish drugmaker is able to grow despite the Danish krone moving against the currencies that predominate its sales..
The Motley Fool June 26, 2009 Brian Orelli	Rumors and Safety Issues -- One Bad Combination There are rumors floating around that a study will show that use of Sanofi's insulin product, Lantus, has an increased risk of cancer.
Pharmaceutical Executive October 1, 2005	Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions.
The Motley Fool July 20, 2006 Stephen D. Simpson	Pfizer's Big Plans Between the launch of inhaled insulin and spending $34 billion, Pfizer has a lot on its plate. Investors, take note.
The Motley Fool August 12, 2011 Evan Niu	One Small Step for Afrezza, One Giant Leap for MannKind Afrezza makes headway toward FDA approval.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
The Motley Fool November 3, 2006 Brian Lawler	Nektar Worth Waiting For? Investors might be getting impatient, but the new insulin the company makes is special.
American Family Physician July 15, 2006 Jennifer D. Goldman-Levine	Insulin Detemir (Levemir) for Diabetes Mellitus Insulin detemir is suitable as basal insulin in a basal-bolus regimen. In limited research, it has been shown to cause slightly fewer episodes of minor hypoglycemia and no weight gain in patients with type 1 and 2 diabetes, which is a benefit that must be balanced against its higher price.
Nursing November 2009 Christine Kessler	Glycemic control in the hospital: How tight should it be? Based on recent studies, the answer to that question remains controversial. This article will explore this issue and present current best practices for caring for a patient in the hospital who has diabetes or hyperglycemia.
The Motley Fool May 20, 2009 Brian Orelli	Joining to Treat, and Beat, Diabetes Medical-device maker Medtronic and drugmaker Eli Lilly are teaming up to co-promote the companies' diabetes products to doctors and patients.
Nurse Practitioner May 2011 Stacey A. Seggelke	Hitting the target for inpatient glycemic management An understanding of glycemic treatment options for hospitalized patients is essential for good patient outcomes.